Apart from Verteporfin, several drugs with a benzisothiazole-dioxide scaffold, which binds to TEAD and disrupts the YAP/TAZ–TEAD interaction, have been studied and we await these drugs entering clinical trials, especially in malignant pleural mesothelioma and breast and lung cancers, where the Hippo pathway is disrupted [66]. Here, YAP1 is linked to lung carcinoma.